Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Alfresa HD Revises Profit Forecasts Downward Due to Losses Caused by Quake
May 16, 2011
- Genzyme's Thymoglobulin Obtains Additional Indication
May 16, 2011
- DSP, CiRA to Jointly Develop Drugs for a Rare, Intractable Disease
May 16, 2011
- MatsumotoKiyoshi HD Maintains “A-”Rating: R&I
May 16, 2011
- New Dosage Approved for Shionogi's Finibax
May 16, 2011
- Astellas Announces Changes in Top Leadership
May 16, 2011
- Assessing Contamination Risk Important in Wake of Nuclear Accident: Mr Igari of JPMA
May 16, 2011
- Takeda Submits 2 sNDAs for Velcade in the US
May 16, 2011
- Expectations High for BI Japan's Prazaxa, 1st Novel Oral Anticoagulant in Half a Century
May 16, 2011
- Japan Is Best Positioned to Help China Strengthen Its New Drug Development Capability: Mr Hasegawa
May 16, 2011
- Chugai Files for Add'l Indication for Herceptin Based in Info in Public Domain
May 16, 2011
- MSs from Wholesalers Provide Valuable Services in Emergency, MRs Feel Small
May 16, 2011
- Japanese Economy Threatened by “Serious Illness” New Keizai Doyukai Chairman Mr Hasegawa
May 16, 2011
- Actemra Approved for SJIA as Additional Indication in US
May 16, 2011
- Drug Makers to Continue Production through Golden Week
May 16, 2011
- Liovel, Nexium Recommended for Approval
May 16, 2011
- CHMP Gives Positive Opinion for Avastin, Xeloda Combination: Roche
May 16, 2011
- Sugi HD: Sales from Dispensing Services Up 16% to ¥24.8 Bil.
May 2, 2011
- CoreMed Offers New Service to Increase Efficiency of eCTD Filing
May 2, 2011
- Korosho to Consider Allowing Home Delivery of OTC Drugs by Pharmacists
May 2, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…